Clinical trials / NCT04706988
Recruiting

Relationship of Airway Microbiota, Endotype and Phenotype in Adult Asthma

Increasing evidence supports that the respiratory microbiota, including viral and bacterial microorganisms, play important roles in respiratory health and disease. Microbial patterns in airways may induce distinctive endotypes of asthma. Previous studies suggest host-microbiota interactions in children may account for the heterogeneity of endotypes and clinical presentations. However, information on such relationship is limited in adults. Furthermore, how the upper airway microbiome is related to asthma endotype…

ClinicalTrials.gov IDNCT04706988
PhaseNot Applicable
Enrollment140
SponsorChinese University of Hong Kong
Age18 Years
SexALL
I'm interested View official listing

Conditions studied

Asthma

About this study

Increasing evidence supports that the respiratory microbiota, including viral and bacterial microorganisms, play important roles in respiratory health and disease. Microbial patterns in airways may induce distinctive endotypes of asthma. Previous studies suggest host-microbiota interactions in children may account for the heterogeneity of endotypes and clinical presentations. However, information on such relationship is limited in adults. Furthermore, how the upper airway microbiome is related to asthma endotype and phenotype is not well understood. Knowledge of microbiota in the airway allows exploration of therapeutic manipulation of the microbiome and targeting the development of asthma prevention strategies and the optimization of asthma treatment.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Subjects aged between 18 and 80 years and have a diagnosis of asthma according to the Global Initiative for Asthma (GINA) document in 2020. * Asthma is defined as those with a consistent history and prior documented evidence of variable airflow obstruction, with evidence of an increase in FEV1 greater than 12% or 200 mL following bronchodilator or bronchial hyperresponsiveness on bronchial provocation testing, when stable. Exclusion Criteria: * Patients with respiratory diseases with other known respiratory diseases including chronic obstructive pulmonary disease, bronchiectasis, tuberculosis (TB)-destroyed lung parenchyma, history of lung resection and lung cancer * Individuals older than 40 years with a smoking history of more than 10 pack-years or significant biomass exposure * Patients currently randomized in other clinical studies * Pregnant women * Current smokers (who have not quit smoking in the past 1 year) * Systemic and intranasal antibiotics treatment within 4 weeks * Signs and symptoms of respiratory tract infections (upper or lower) within 4 weeks

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.